The Financial Express13h
AstraZeneca’s Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
STAT6h
AstraZeneca, Daiichi Sankyo win first U.S. approval for key cancer drug
A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...
2 Quantum Computing Stocks That Could Be a Once-in-a-Lifetime Opportunity
Trapped-ion quantum computing leader IonQ (NYSE: IONQ) is emerging as a potential leader in the commercialization of quantum ...
Prediction: this FTSE 250 trust will beat Rolls-Royce shares over the next 5 years
Our writer reckons this tech-driven FTSE 250 investment trust has what it takes to outperform Rolls-Royce shares between now ...
pharmaphorum23h
AstraZeneca joins KRAS push in cancer with Chinese deal
AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the ...
Tuko on MSN11h
Meet 18 companies in Kenya recognised and certified as top employers in 2025.
The Top Employers Institute has recognised 18 companies in Kenya for their excellence in HR practices, certifying them as Top ...